Three things to know:
1. Merck saw its worldwide sales increase 5 percent to $11 billion in the fourth quarter of 2018, including a 3 percent negative effect from foreign exchange. Its full-year total sales also increased 5 percent to $42.3 billion.
2. An increase in pharmaceutical sales was driven primarily by growth in the company’s oncology and vaccine units. In addition, lost sales due to a cyberattack in June 2017 unfavorably affected the drugmaker’s revenue for the full year of 2018 by $150 million.
3. For full-year 2018, Merck said pharmaceutical sales increased 6 percent to $37.7 billion, thanks to growth in its oncology, vaccines and hospital acute care businesses.
More articles on pharmacy:
Cancer therapy prices prevent access to treatment, WHO says
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
